Overview
Isoflavones (genistein, daidzein, glycitein) are phytoestrogens found primarily in soy products. They bind estrogen receptors (ERα and ERβ) with weak agonist/antagonist activity and are among the most microbiome-dependent dietary bioactives — their clinical effects depend on whether the individual's gut bacteria can convert daidzein to equol, the most potent isoflavone metabolite.
Microbiome Dependence
- Only ~30-50% of Western populations harbor equol-producing bacteria (primarily certain Clostridia and gordonibacter). "Equol producers" have stronger clinical responses to soy isoflavones than "non-producers."
- Equol production is a function of gut microbiome composition, making isoflavone efficacy a pharmacomicrobiomics question.
Disease Relevance
- Endometriosis: Isoflavones may modulate estrogen-dependent lesion growth [1].
- MS: Dietary isoflavones studied as immunomodulatory intervention in EAE models [2] [3].
- CVD: Polyphenol bioavailability including isoflavones linked to cardiovascular protection [4].
- IBD: Anti-inflammatory effects in IBD models [5].
Cross-References
- estrobolome — microbial estrogen metabolism (Primitive 7)
- gordonibacter — equol-producing gut bacterium
- polyphenols — broader class of plant bioactives
- pharmacomicrobiomics — drug/nutraceutical efficacy depends on microbiome